2) Here’s a simplified diagram of hypothetical mechanisms. (Stay tuned. We’re building this out to be dynamic with more detailed info & additional hypotheses it.)
3) We’ve been tracking the microbiome before, during, & after AmoxiClav.
We saw shifts in my microbiome during remission while on AmoxiClav.
For example: ↓ gram-negative bacteria ↑ dopamine-producing bacteria
4) We have additional microbiome data collected before, during, & after AmoxiClav from over a dozen patients, which we are currently analyzing. We’ll see if my data was just an N=1 or if we find similar trends in the pooled data.
5) We’re also looking at changes in the immune system. Check out my N=1 cytokine results before, during, & after a transient remission event while on AmoxiClav.
This could be downstream of many possible causes & not due to the antibiotic directly acting on immune cells, but ...
6) It is possible that Amoxicillin has direct immunomodulatory effects.
7) In addition to changes in cytokines, we saw significant changes in classical monocytes with single-cell immune profiling. (Can’t draw any conclusions with my N=1 here, but it’s interesting & we’re going to follow up on it.)
8) One could argue that this could be downstream of treating reactivated infections or modifying the microbiome rather than direct effects. It’s hard to prove causality & there hasn’t been much research into more targeted immune effects of antibiotics (like using single-cell.)
9) Another one of our favorite hypotheses, which wasn’t part of our original ideas before we did the pilot study, is that AmoxiClav affects the glutamate system.
@katboniface came up with this idea and has been diving deep into it. We call her #TheGlutamateBoss.
10) Beta lactam antibiotics, like AmoxiClav (& Amoxicillin to a lesser extent), have direct effects on glutamate transporters, but this is not well studied (yet.)
She has also has a ton of X posts about glutamate & antibiotics: x.com/search?q=gluta…
We're excited to share that Kat's hypothesis has sparked some work in the academic setting that might tell us more about possible glutamate mechanisms of remission!
I've seen a lot of posts today about the BC007 negative trial results & a lot of good thoughts about issues with this. I'll collect people's thoughts that I think are relevant in this thread.
It's really frustrating to see this happen. Obviously the negative results might be real, but with all of the issues with the trial design, like the outcome measures used (explained in this thread), I worry that BC007 will be "put on the shelf". People will think, "this doesn't work ... Moving on to the next trial."
What if it does actually work in a subset of people with #LongCovid, though? What if it would work for many if tried in combination with other interventions to hit the system from multiple angles? What if it did even actually work for a subset of people in this trial, but for Sx other than fatigue that weren't measured?
It's complicated. 😞 We need a new way of exploring diagnosis & treatment for complex, chronic, multi-system disease.
Outcome measures.
See the questionnaire used in the study in the Tweet before this one.
@bryan_johnson said that he has congenitally narrow internal jugular veins & was able to watch with real-time imaging how his posture affects the blood flow through them.
This blood flow is important, because if there's not enough it can lead to high pressure in the brain.
I also have restricted blood flow through my internal jugular veins - not from the veins themselves being narrow, but from them getting compressed by structures in my neck (in between my C1 vertebrae & a bone called the styloid.)
One of our goals at @renegaderes is to bridge the gap between anecdotes & trials.
We run systematic, decentralized studies by organizing patients to work with their own healthcare providers & then pooling the data.
In addition to our direct research, we want to connect people working on different aspects of the problem (patients, caregivers, clinicians, fundamental researchers, clinical researchers, etc.) They can all inform each other's work.
The roundtable last Friday is an example of building connections. The main goal was to connect people & ideas (patient anecdotes, clinician experience, & the few published case series to the molecular basis research presented in Ron Davis's meeting).
In @remissionbiome we refer to "remission events". They can be short-lived, like even minutes, but during them, ALL Sx of #MECFS go away. You feel like a healthy person.
I've found that most people don't understand what I mean when I describe it ...
They get confused that I would refer to something as short as a few mins as a "remission event".
But for the people who have had them, it makes sense.
In order to experience these "remission events" as distinct & obvious, the person must be constantly having Sx when they are not in a remission event, to contrast with this switch flip. Constantly having a feeling in their body that can then suddenly go away.